<--- Back to Details
First PageDocument Content
Medicine / Biotechnology / Monoclonal antibodies / Glycoproteins / Monoclonal antibody therapy / Humanized antibody / Phage display / Fusion protein / Bispecific monoclonal antibody / Biology / Immunology / Immune system
Date: 2015-03-26 04:00:20
Medicine
Biotechnology
Monoclonal antibodies
Glycoproteins
Monoclonal antibody therapy
Humanized antibody
Phage display
Fusion protein
Bispecific monoclonal antibody
Biology
Immunology
Immune system

COVER CONFERENCE-AT-A-GLANCE Eleventh Annual HOTEL & TRAVEL

Add to Reading List

Source URL: www.giievent.tw

Download Document from Source Website

File Size: 2,79 MB

Share Document on Facebook

Similar Documents

Cover Conference-at-a-Glance Final Agenda Eighth Annual

Cover Conference-at-a-Glance Final Agenda Eighth Annual

DocID: 1rglJ - View Document

F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics Strong academic bridge supports F-star’s leading, innovative position in immuno-oncology and bispeci

F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics Strong academic bridge supports F-star’s leading, innovative position in immuno-oncology and bispeci

DocID: 1r0k4 - View Document

F-star Announces Initiation of a Phase 1 Clinical Trial for FS102 for the Treatment of HER2-Positive Breast and Gastric Cancer CAMBRIDGE, UK – 9 JanuaryF-star, a biopharmaceutical company focused on oncology and

F-star Announces Initiation of a Phase 1 Clinical Trial for FS102 for the Treatment of HER2-Positive Breast and Gastric Cancer CAMBRIDGE, UK – 9 JanuaryF-star, a biopharmaceutical company focused on oncology and

DocID: 19G4J - View Document

F-star Announces the Formation of Second Asset-Centric Vehicle, F-star Beta Ltd F-star Beta to Develop Oncology and Immuno-Oncology Compounds Cambridge, UK, 4 NovemberF-star an oncology-focused biopharmaceutical c

F-star Announces the Formation of Second Asset-Centric Vehicle, F-star Beta Ltd F-star Beta to Develop Oncology and Immuno-Oncology Compounds Cambridge, UK, 4 NovemberF-star an oncology-focused biopharmaceutical c

DocID: 19yql - View Document

COVER CONFERENCE-AT-A-GLANCE Eleventh Annual  HOTEL & TRAVEL

COVER CONFERENCE-AT-A-GLANCE Eleventh Annual HOTEL & TRAVEL

DocID: 18YSW - View Document